mRNA合成・製造市場：サービス別、サービスタイプ別、製造プロセス別、製造規模別、技術別、用途別、用途別、エンドユーザー別-2025-2030年世界予測

mRNA合成・製造市場は、2023年に24億8,000万米ドルと評価され、2024年には27億1,000万米ドル、CAGR 9.35%で成長し、2030年には46億5,000万米ドルに達すると予測されています。

mRNAの合成と製造は、バイオテクノロジー分野における変革技術として登場し、技術革新を推進し、治療薬やワクチン開発を再定義しています。最近の世界の健康課題を受け、効率的でスケーラブルかつ高品質なmRNA生産への需要が加速しています。このようなダイナミックな環境では、中核となるプロセス、市場促進要因、将来を形作る戦略的イニシアチブについて、微妙な理解が求められます。

mRNA生産の情勢は、急速な技術進歩と進化する規制の枠組みによって特徴づけられています。mRNAのキャッピング、製剤化、試験管内転写、精製における新しい技術は、生産のスピードと質を向上させるだけでなく、新たな業界標準を設定しつつあります。市場が拡大するにつれ、利害関係者はプロセスの選択、技術の適応、リソースの配分に関する複雑な決定にますます直面するようになっています。

研究機関から大手製薬企業まで、業界関係者は競争優位性を維持するために次世代製造能力に投資しています。先進的な酵素キャッピングとキャップアナログ手法の統合は、保管と流通ロジスティクスの進化と相まって、顧客特異的なmRNA製品と標準化されたmRNA製品の両方のデリバリーを合理化しています。この入門編では、mRNA合成・製造市場に影響を与える様々な要素について掘り下げて解説し、さらなる分析と戦略立案のための枠組みを提供します。

mRNA合成・製造市場の変革

mRNA合成・製造業界は、従来のパラダイムを再定義し、革新的な成長への道を切り開く、変革的なシフトを目の当たりにしています。老舗企業も新興企業も、かつてない世界の需要に後押しされ、新たなチャンスをつかむために技術的強化や斬新なアプローチを取り入れています。

遺伝子工学とコドンの最適化における急速な進歩は、試験管内転写プロセスの大幅な改善につながりました。自動化されたワークフローが統合されたことで、生産期間が短縮されただけでなく、緊急のヘルスケアニーズに対応する上で重要な要素であるスケーラビリティと再現性も向上しました。さらに、公衆衛生上の危機の緊急性に後押しされた規制の進化が、新しい製造技術の採用を加速し、承認サイクルの迅速化と品質管理の透明性向上を可能にしています。

こうした変革的なシフトは、先進的な脂質ナノ粒子（LNP）製剤と酵素キャッピング技術への厳格な投資によって増幅されています。これらの手法の複合的な進化は、治療とワクチンの両方の用途に対応するための強固な枠組みを提供します。さらに、複雑な世界サプライチェーンの課題に直面しても、高品質のmRNA製品が効率的に目的の市場に到達するためには、保管・流通ロジスティクスの強化が極めて重要です。

今日の市場は、カスタム化と特定の顧客の要求へのシフトによって定義されています。顧客固有の注文や研究仕様に合わせたカスタムmRNA合成は、カタログや既製のmRNAセレクションに焦点を当てた従来のアプローチと肩を並べるようになりました。この進化は、実験的研究から大規模な臨床応用に至るまで、多様な要求に応えるという業界のコミットメントを反映しています。要するに、こうした市場のシフトは、従来の大量生産から、より機敏で適応性が高く、精度に焦点を当てた製造エコシステムへの移行を裏付けるものです。

mRNA製造における主要なセグメンテーションの洞察

mRNA合成・製造の市場セグメンテーションを詳細に調べると、特定の要件や応用領域に対応する複数の側面が明らかになります。サービスの観点から市場を分析すると、キャッピングとテーリング、製剤化、in silico設計、改変と最適化、精製と品質管理、保管と流通、鋳型DNA調製などの研究が、技術的な複雑さを理解するための基礎的な枠組みを提供します。さらに、サービスタイプの違いを考慮すると、市場はカスタムmRNA合成と標準mRNA製造の両方を評価することができます。前者は顧客固有のmRNA注文やオーダーメイドの研究仕様と密接に関連しており、後者はカタログ化されたmRNAバリアントや既製のmRNAセレクションを含み、多様な運営モデルを反映しています。

製造プロセスに基づくセグメンテーション分析では、高度なLNP製剤技術、キャップ類似体と組み合わせた酵素的キャッピング、コドンの最適化を伴う遺伝子工学、さらにはin vitro転写技術、プラスミドDNAテンプレートの使用、ポリアデニル化、RNA精製などの革新的技術に焦点を当てています。この視点は、製品を差別化し、市場のポジショニングに影響を与える重要な技術的・プロセス的要因を捉えています。同様に重要なのは、製造規模に基づくセグメンテーションであり、商業規模、ラボ規模、パイロット規模での操作の実際と課題に焦点を当て、それぞれに独自の操作フレームワークと経済的意味を提示しています。

技術に基づくセグメンテーションでは、in vitro合成とin vivo合成という二項対立が導入され、それぞれが独自の利点と限界を持つ特殊な技術的アプローチを示しています。アプリケーションに基づくセグメンテーションでは、さらに市場を治療薬とワクチンに区分します。ここでは、がん、感染症、希少疾患に焦点を当てた治療薬セグメントは、臨床要件と革新的ソリューションの複雑な相互作用を示します。一方、ワクチン分野は予防ワクチンと治療ワクチンに多様化し、予防と治療の戦略的バランスが強調されています。

用途やエンドユーザーのセグメンテーションといった付加的な側面は、市場力学に対する微妙な洞察を提供します。用途の観点では、ヒト用と動物用を区別し、目標とする製品設計と性能基準を反映します。一方、エンドユーザー・セグメンテーションは、学術研究機関、製造受託機関、製薬・バイオテクノロジー企業間の相互関係をマッピングすることで明確化し、学術研究機関内では政府研究機関や大学研究室に基づいてさらに区別します。この階層的なセグメンテーションは、市場の多面的な性質を浮き彫りにし、さまざまな顧客セグメントの正確なニーズを満たす、オーダーメイドの戦略と的を絞った製品イノベーションのためのロードマップを提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で感染症の発生が増加
    • バイオテクノロジー企業と教育機関のパートナーシップ
  • 抑制要因
    • mRNAに関連する複雑でコストのかかる製造プロセス
  • 機会
    • がん治療における新たなmRNAの応用
    • データ分析とAIを統合してmRNA配列の設計と最適化を強化
    • 政府および民間団体からの多額の資金と投資
  • 課題
    • mRNA合成・製造に関連する倫理的な懸念
    • mRNAの複雑な規制状況をナビゲートする難しさ
• 市場セグメンテーション分析
  • サービス：修正および最適化サービスの利用の増加は、安定性と翻訳効率の向上に重点を置いています。
  • サービスタイプ：パーソナライズされたソリューションの提供、バイオテクノロジーの新興企業や調査機関の誘致におけるカスタムmRNA合成の大幅な活用
  • 製造プロセス：タンパク質収量を最大化し、最適な遺伝子発現を確保するために、遺伝子工学とコドン最適化プロセスを大幅に採用
  • 製造規模：成長する製薬会社と既存のバイオテクノロジー企業による商業規模の生産の増加
  • 技術：迅速な生産サイクルと合成プロセスに提供される制御レベルにより、in vitro合成の採用が増加しています。
  • 応用：ワクチンにおけるmRNA合成・製造の役割の拡大
  • 使用法：ヒト用mRNAベースの治療薬およびワクチンの必要性の高まり
  • エンドユーザー：製薬会社とバイオテクノロジー会社は、ワクチンや治療薬の開発における可能性を秘めたmRNA技術に多額の投資を行っています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 mRNA合成・製造市場：サービス別

• キャッピングとテーリング
• 処方
• インシリコデザイン
• 修正と最適化
• 精製と品質管理
• 保管と配送
• テンプレートDNAの準備

第7章 mRNA合成・製造市場：サービスタイプ別

• カスタムmRNA合成
  • 顧客固有のmRNA注文
  • カスタマイズされた調査仕様
• 標準的なmRNA生産
  • カタログ化されたmRNA変異体
  • 既製のmRNAセレクション

第8章 mRNA合成・製造市場：製造工程別

• 高度なLNP製剤技術
• 酵素キャッピングとキャップ類似体
• 遺伝子工学とコドン最適化
• インビトロ転写
• プラスミド DNAテンプレート
• ポリアデニル化
• RNA精製技術

第9章 mRNA合成・製造市場製造規模別

• 商業規模
• ラボスケール
• パイロットスケール

第10章 mRNA合成・製造市場：技術別

• インビトロ合成
• 生体内合成

第11章 mRNA合成・製造市場：用途別

• 治療薬
  • がん
  • 感染症
  • 希少疾患
• ワクチン
  • 予防ワクチン
  • 治療ワクチン

第12章 mRNA合成・製造市場用途別

• 人間への使用
• 獣医学的使用

第13章 mRNA合成・製造市場：エンドユーザー別

• 学術調査機関
  • 政府の調査機関
  • 大学の研究室
• 契約製造組織
• 製薬・バイオテクノロジー企業

第14章 南北アメリカのmRNA合成・製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第15章 アジア太平洋地域のmRNA合成・製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第16章 欧州・中東・アフリカのmRNA合成・製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第17章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
• Bio-Synthesis Inc.
• Creative Biogene
• Creative Biolabs
• Croyez Bioscience Co., Ltd.
• Danaher Corporation
• FUJIFILM Wako Pure Chemical Corporation
• Genewiz by Azenta Life Sciences
• GenScript Biotech Corporation
• Jena Bioscience GmbH by Enzo Biochem Inc.
• Lonza Group Ltd.
• Merck KGaA
• New England Biolabs, Inc.
• PackGene Biotech, Inc.
• Promega Corporation
• Samsung Biologics Co., Ltd.
• Sartorius AG
• ST Pharm
• System Biosciences, LLC
• Takara Bio Inc.
• Telesis Bio Inc.
• Thermo Fisher Scientific Inc.
• TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
• WuXi Biologics（Cayman）Inc

LIST OF FIGURES

• FIGURE 1. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-CURRENCY
• FIGURE 2. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-LANGUAGE
• FIGURE 3. MRNA SYNTHESIS & MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 4. MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
• FIGURE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 27. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 29. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 30. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 31. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 32. MRNA SYNTHESIS & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 33. MRNA SYNTHESIS & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MRNA SYNTHESIS & MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MRNA SYNTHESIS & MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 92. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 95. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 96. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 99. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 100. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 102. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 103. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 104. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 105. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 108. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 109. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 110. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 113. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 115. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 116. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 117. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 118. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 121. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 122. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 123. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 125. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 126. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 128. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 129. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 130. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 131. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 134. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 135. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 136. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 138. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 140. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 142. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 144. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 148. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 150. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 152. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 153. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 154. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 155. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 156. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 157. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 158. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 159. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 162. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 163. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 164. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. AUSTRALIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 166. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 167. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 168. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 169. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 170. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 171. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 172. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 175. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 176. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 177. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 179. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 180. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 182. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 183. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 184. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 185. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 188. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 189. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 190. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. INDIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 192. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 193. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 195. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 196. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 197. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 198. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 199. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 201. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 202. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 203. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. INDONESIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 205. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 206. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 208. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 209. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 210. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 211. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 214. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 215. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 216. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. JAPAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 218. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 219. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 220. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 221. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 222. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 223. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 224. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 227. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 228. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 229. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. MALAYSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 231. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 232. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 233. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 234. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 235. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 236. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 237. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 238. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 240. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 241. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 242. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. PHILIPPINES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 244. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 245. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 247. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 248. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 249. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 250. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 253. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 254. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 255. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 256. SINGAPORE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 258. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 260. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 262. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 266. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 267. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 268. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 269. SOUTH KOREA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 270. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 271. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 273. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 274. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 275. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 276. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 277. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 279. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 280. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 281. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 282. TAIWAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 283. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 284. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 285. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 286. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 287. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 288. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 289. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 290. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 291. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 292. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 293. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 294. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 295. THAILAND MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 296. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 297. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 298. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 299. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 300. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 301. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
• TABLE 302. VIETNAM MRNA SYNTHESIS & MANUFACTURING MARKET

The mRNA Synthesis & Manufacturing Market was valued at USD 2.48 billion in 2023 and is projected to grow to USD 2.71 billion in 2024, with a CAGR of 9.35%, reaching USD 4.65 billion by 2030.

mRNA synthesis and manufacturing have emerged as transformative technologies in the biotechnology sector, driving innovation and redefining therapeutic and vaccine development. In the wake of recent global health challenges, the demand for efficient, scalable, and high-quality mRNA production has accelerated. This dynamic environment calls for a nuanced understanding of the core processes, market drivers, and strategic initiatives that are shaping the future.

The landscape of mRNA production is marked by rapid technological advancements and evolving regulatory frameworks. Novel techniques in mRNA capping, formulation, in vitro transcription, and purification are not only enhancing the speed and quality of production but are also setting new industry standards. As the market expands, stakeholders are increasingly confronted with complex decisions regarding process selection, technology adaptation, and resource allocation.

Industry participants-from research institutes to major pharmaceutical corporations-are investing in next-generation manufacturing capabilities to maintain competitive advantage. The integration of advanced enzymatic capping and cap analogue methodologies, combined with the evolution of storage and distribution logistics, is streamlining the delivery of both client-specific and standardized mRNA products. This introductory section sets the stage for an in-depth exploration of the various elements that influence the mRNA synthesis and manufacturing market, providing a framework for further analysis and strategic planning.

Transformative Shifts in the mRNA Synthesis & Manufacturing Landscape

The mRNA synthesis and manufacturing industry is witnessing transformative shifts that are redefining traditional paradigms and paving the way for innovative growth. Established companies and emerging players alike are embracing technological enhancements and novel approaches to seize new opportunities, driven by unprecedented global demand.

Rapid advancements in genetic engineering and codon optimization have led to significant improvements in in vitro transcription processes. The integration of automated workflows has not only reduced production timelines but has also increased scalability and reproducibility-critical factors in responding to urgent healthcare needs. Moreover, regulatory evolutions, driven by the urgency of public health crises, have accelerated the adoption of new manufacturing technologies, enabling faster approval cycles and enhanced transparency in quality control.

These transformative shifts are amplified by rigorous investments in advanced lipid nanoparticle (LNP) formulation and enzymatic capping technologies. The combined evolution of these methodologies offers a robust framework for addressing both therapeutic and vaccine applications. Additionally, enhancements in storage and distribution logistics have been pivotal in ensuring that high-quality mRNA products reach their intended markets efficiently, even in the face of complex global supply chain challenges.

The market today is defined by a shift towards customization and specific client requirements. Custom mRNA synthesis, driven by client-specific orders and tailored research specifications, now stands shoulder-to-shoulder with conventional approaches that focus on cataloged or off-the-shelf mRNA selections. This evolution reflects the industry's commitment to meeting diverse demands, ranging from experimental research to large-scale clinical applications. In essence, these market shifts underscore a transition from conventional mass production to a more agile, adaptable, and precision-focused manufacturing ecosystem.

Key Segmentation Insights in mRNA Manufacture

A detailed examination of market segmentation in mRNA synthesis and manufacturing reveals multiple dimensions that cater to specific requirements and application domains. Analyzing the market from the perspective of services, the study of capping and tailing, formulation, in silico design, modification and optimization, purification and quality control, storage and distribution, and template DNA preparation provide a foundational framework for understanding technological intricacies. Moreover, when considering service type distinctions, the market is evaluative of both custom mRNA synthesis and standard mRNA production. The former is intricately linked to client-specific mRNA orders and tailored research specifications, while the latter encompasses cataloged mRNA variants and off-the-shelf mRNA selections, reflecting diverse operational models.

The segmentation analysis based on the manufacturing process highlights innovations such as advanced LNP formulation technology, enzymatic capping combined with cap analogues, genetic engineering with codon optimization, as well as in vitro transcription techniques, plasmid DNA template use, polyadenylation, and RNA purification. This perspective captures the critical technological and process-driven factors that differentiate products and influence market positioning. Equally important is the segmentation based on manufacturing scale, which concentrates on the practicalities and challenges of commercial scale, lab scale, and pilot scale operations, each presenting unique operational frameworks and economic implications.

Further segmentation based on technology introduces the dichotomy between in vitro synthesis and in vivo synthesis, each representing specialized technological approaches with their own advantages and limitations. Application-based segmentation further dissects the market into therapeutics and vaccines. Here, the therapeutic segment, with its focus on cancer, infectious diseases, and rare diseases, demonstrates a complex interplay of clinical requirements and innovative solutions. Meanwhile, the vaccine segment diversifies into prophylactic vaccines and therapeutic vaccines, highlighting a strategic balance between prevention and treatment.

Additional dimensions such as usage and end-user segmentation offer nuanced insights into market dynamics. The usage perspective distinguishes between human and veterinary use, reflecting targeted product design and performance criteria. Meanwhile, end-user segmentation provides clarity by mapping the interrelationships between academic and research institutes, contract manufacturing organizations, and pharmaceutical and biotechnology companies, with further differentiation within academic and research institutes based on government research bodies and university laboratories. This layered segmentation highlights the multifaceted nature of the market, offering a roadmap for tailored strategies and targeted product innovations that meet the precise needs of different customer segments.

Based on Services, market is studied across Capping & Tailing, Formulation, In Silico Design, Modification & Optimization, Purification & Quality Control, Storage & Distribution, and Template DNA Preparation.

Based on Service Type, market is studied across Custom mRNA Synthesis and Standard mRNA Production. The Custom mRNA Synthesis is further studied across Client-Specific mRNA Orders and Tailored Research Specifications. The Standard mRNA Production is further studied across Cataloged mRNA Variants and Off-the-Shelf mRNA Selections.

Based on Manufacturing Process, market is studied across Advanced LNP Formulation Technology, Enzymatic Capping & Cap Analogues, Genetic Engineering & Codon Optimization, In Vitro Transcription, Plasmid DNA Template, Polyadenylation, and RNA Purification Techniques.

Based on Manufacturing Scale, market is studied across Commercial Scale, Lab Scale, and Pilot Scale.

Based on Technology, market is studied across In Vitro Synthesis and In Vivo Synthesis.

Based on Application, market is studied across Therapeutics and Vaccines. The Therapeutics is further studied across Cancer, Infectious Diseases, and Rare Diseases. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.

Based on Usage, market is studied across Human Use and Veterinary Use.

Based on End-User, market is studied across Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutes is further studied across Government Research Bodies and University Laboratories.

Key Regional Insights Influencing Market Dynamics

The geographic dimension of mRNA synthesis and manufacturing is characterized by varied regional trends and strategic imperatives. Analysis across the Americas has revealed robust investment in state-of-the-art research and development facilities, driven by both private and public funding that positions the region at the forefront of technological innovation. This dynamic is propelled by strong collaborations between academic institutions and the pharmaceutical industry, fostering an ecosystem conducive to rapid product iteration and market responsiveness.

Turning to the Europe, Middle East & Africa region, the focus is on regulatory harmonization and quality control standards that are essential for both local markets and broader international trade. Increased governmental support paired with strategic partnerships in biotech research has enabled significant inroads in mRNA technology. This region's evolved regulatory framework not only supports innovative research but also accelerates the path from laboratory discovery to clinical application, thereby enhancing overall market competitiveness.

In the Asia-Pacific region, the market is buoyed by rapid industrial growth, extensive investments in manufacturing infrastructure, and a burgeoning talent pool of scientific professionals. Innovations here are underscored by a commitment to scale commercial production while maintaining rigorous standards in laboratory research. The integration of advanced manufacturing processes with local expertise supports both customized and standardized production models, driving efficiency and ensuring that emerging products meet global quality benchmarks. Together, these regional insights play a pivotal role in shaping market strategies and investment decisions for companies operating across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping Industry Innovation

The competitive landscape is defined by the presence of several key companies that continuously drive innovation and market growth in mRNA synthesis and manufacturing. Leading firms such as Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited and Bio-Synthesis Inc. have been instrumental in advancing client-specific service offerings, leveraging their robust research capabilities to meet specialized demands. Creative Biogene and Creative Biolabs contribute significantly by combining tailored research with comprehensive standard production platforms, thereby bridging the gap between novelty and consistency.

Another critical group includes Croyez Bioscience Co., Ltd. and Danaher Corporation, both of which invest heavily in state-of-the-art production technologies that improve process automation and yield. FUJIFILM Wako Pure Chemical Corporation and Genewiz by Azenta Life Sciences focus on providing high-quality enzymes and reagents that are essential to enhancing the precision and robustness of mRNA manufacturing. GenScript Biotech Corporation and Jena Bioscience GmbH by Enzo Biochem Inc. continue to influence the market through their dedicated advancements in process optimization and genetic engineering techniques.

The manufacturing scale is further impacted by major industry leaders such as Lonza Group Ltd. and Merck KGaA, which have set benchmarks in large-scale production workflows as well as quality control mechanisms. New England Biolabs, Inc., alongside PackGene Biotech, Inc. and Promega Corporation, are well-regarded for their contributions to developing efficient pilot and lab scale production systems while maintaining consistency across commercial scale outputs. Companies like Samsung Biologics Co., Ltd. and Sartorius AG have also brought precision and operational excellence to the forefront, expanding production capacities and streamlining logistics.

Additional market influencers include ST Pharm and System Biosciences, LLC, who invest in cutting-edge research and process innovation. Takara Bio Inc. and Telesis Bio Inc. further add to the competitive momentum by focusing on integrated manufacturing solutions that blend in vitro synthesis with advanced analytic capabilities. Thermo Fisher Scientific Inc. and TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, with their diverse service portfolios, have also positioned themselves as leaders in both custom and standard mRNA production methodologies. Finally, WuXi Biologics (Cayman) Inc. rounds out an impressive list of companies dedicated to advancing production capabilities, reinforcing the industry's commitment to quality and innovation at every stage of mRNA synthesis and manufacturing.

The report delves into recent significant developments in the mRNA Synthesis & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited, Bio-Synthesis Inc., Creative Biogene, Creative Biolabs, Croyez Bioscience Co., Ltd., Danaher Corporation, FUJIFILM Wako Pure Chemical Corporation, Genewiz by Azenta Life Sciences, GenScript Biotech Corporation, Jena Bioscience GmbH by Enzo Biochem Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, Inc., PackGene Biotech, Inc., Promega Corporation, Samsung Biologics Co., Ltd., Sartorius AG, ST Pharm, System Biosciences, LLC, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, and WuXi Biologics (Cayman) Inc. Actionable Recommendations for Industry Leaders in mRNA Manufacturing

In the face of rapid technological evolution and competitive market forces, industry leaders must adopt proactive strategies to maintain and enhance their market positioning. To thrive in this environment, companies should consider the following actionable recommendations:

Invest in Continuous Process Optimization: The rapid pace of technological advancements demands ongoing investments in process innovation. Establish dedicated research and development units to continuously refine production techniques, focusing on areas such as advanced LNP formulation technology, enzymatic capping innovations, and state-of-the-art genetic engineering practices. Regular audits of in vitro transcription, plasmid template preparation, and RNA purification technologies will not only drive operational efficiencies but also ensure compliance with emerging regulatory standards.

Embrace Flexible Production Models: With the market segmented by manufacturing scale-from lab and pilot scale to full commercial production-it is crucial to build adaptive production units that can scale based on demand fluctuations. Flexible manufacturing setups allow firms to optimize resource allocation and manage risks associated with overproduction or underutilization of facilities. Adopting modular manufacturing strategies can help streamline transitions between different production scales, ensuring a seamless response to shifting market dynamics.

Strengthen Collaborative Networks: In today's competitive landscape, forging strategic partnerships is key to unlocking synergies and driving innovation. Collaborations with academic research institutions, government research bodies, and private sector leaders can facilitate the exchange of expertise and best practices. Such networks not only enhance technological capabilities but also provide opportunities for joint research initiatives, faster adoption of breakthrough technologies, and improved market outreach.

Prioritize Technology Integration: With segmentation based on service type and technological approaches-whether in vitro or in vivo synthesis-integrating advanced analytics and process automation is critical. Utilize digital twin technology and real-time data monitoring systems to optimize manufacturing workflows, improve quality control, and reduce production bottlenecks. Embracing Industry 4.0 principles will enable organizations to unlock efficiencies and make data-driven decisions that enhance overall operational performance.

Diversify Product Portfolios: Expanding product offerings to include both custom mRNA synthesis and standardized production allows companies to serve a broader segment of the market. By tailoring solutions to meet specific client needs-whether for client-specific orders or cataloged mRNA variants-businesses can capture a wider audience while mitigating risks associated with relying on a single product line. Diversification also opens up new revenue streams, enhances market resilience, and fosters a customer-centric approach to product development.

Focus on Regulatory Compliance and Quality Assurance: Given the critical impact of quality control in mRNA manufacturing, robust systems to ensure regulatory compliance are indispensable. Regular training, process audits, and investments in advanced quality control technologies will minimize risks and build consumer trust. Establishing transparent and rigorous documentation practices is essential for navigating regulatory landscapes and sustaining long-term market viability.

Invest in Workforce Development: As technological complexity increases, so does the need for skilled personnel. Industry leaders should prioritize training and development programs to equip their workforce with the latest techniques in mRNA synthesis and manufacturing. Enhancing technical expertise not only improves operational efficiency but also drives innovation, ensuring that companies remain agile in the face of emerging industry trends.

Pursue Market Expansion Strategically: Finally, a thorough understanding of regional market dynamics-across the Americas, Europe, Middle East & Africa, and Asia-Pacific-should inform expansion strategies. Tailoring market entry plans and product offerings to the unique demands and regulatory environments of each region can unlock new opportunities and bolster international growth. Overall, strategic investments in process innovation, talent development, and robust quality assurance practices will position industry leaders for sustainable success in a competitive and rapidly evolving market.

Conclusion: Embracing Innovation for Future Growth

The mRNA synthesis and manufacturing landscape is characterized by rapid innovation, complex segmentation, and expansive market opportunities. As industry leaders continue to leverage advanced manufacturing processes, integrate cutting-edge technology solutions, and foster strategic collaborations, the stage is set for a new era of precision medicine and breakthrough therapeutic solutions.

This comprehensive analysis underscores the importance of continuous process optimization, flexible production models, and the integration of state-of-the-art technologies. The segmentation insights reveal a market that is as diverse in its applications as it is in its methodologies. Whether it is the intricate processes involved in enzymatic capping, the precision of genetic engineering, or the adaptability required for various manufacturing scales, each facet contributes to a vibrant and competitive ecosystem.

Moreover, regional insights highlight that global collaboration and tailored strategies are pivotal to navigating the unique challenges and opportunities present in different geographies. With major players driving innovation and setting high benchmarks for quality and efficiency, the future of mRNA synthesis and manufacturing looks not only promising but fundamentally transformative.

In conclusion, by embracing a culture of innovation, proactive market expansion, and continuous improvement, stakeholders can unlock unprecedented growth and revolutionize the manner in which life-saving therapies and vaccines are developed. The journey ahead calls for a steadfast commitment to quality, agility, and visionary leadership, ensuring that the full potential of mRNA technology is realized in both current and future applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of infectious diseases across the globe
    • 5.1.1.2. Partnerships between biotech firms and educational institutions
  • 5.1.2. Restraints
    • 5.1.2.1. Complex and costly manufacturing processes associated with mRNA
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging mRNA applications in cancer therapeutics

• 5.1.3.2. Integrating data analytics and AI to enhance mRNA sequence design and optimization
• 5.1.3.3. Significant funding and investment from governments and private entities
• 5.1.4. Challenges
  • 5.1.4.1. Ethical concerns associated with mRNA synthesis & manufacturing

• 5.1.4.2. Diificulties in navigating the complex regulatory landscape for mRNA
• 5.2. Market Segmentation Analysis
  • 5.2.1. Services: Increasing usage of the modification & optimization services focuses on enhancing stability and translational efficiency
  • 5.2.2. Service Type: Significant custom mRNA synthesis utilization in delivering personalized solutions, attracting biotech startups and research institutions
  • 5.2.3. Manufacturing Process: Substantial adoption of genetic engineering & codon optimization process for maximizing protein yield and ensuring optimal gene expression
  • 5.2.4. Manufacturing Scale: Increased commercial scale production driven by growing pharmaceutical companies and established biotech firms
  • 5.2.5. Technology: Rising adoption of in vitro synthesis due to its rapid production cycle and the control level offered over the synthesis process
  • 5.2.6. Application: Expanding role of mRNA synthesis & manufacturing for the vaccines
  • 5.2.7. Usage: Evolving need for mRNA-based therapeutics and vaccines for humans usage
  • 5.2.8. End-User: Pharmaceutical & biotechnology companies are heavily invested in mRNA technology for its potential in vaccine and therapeutic development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Synthesis & Manufacturing Market, by Services

• 6.1. Introduction
• 6.2. Capping & Tailing
• 6.3. Formulation
• 6.4. In Silico Design
• 6.5. Modification & Optimization
• 6.6. Purification & Quality Control
• 6.7. Storage & Distribution
• 6.8. Template DNA Preparation

7. mRNA Synthesis & Manufacturing Market, by Service Type

• 7.1. Introduction
• 7.2. Custom mRNA Synthesis
  • 7.2.1. Client-Specific mRNA Orders
  • 7.2.2. Tailored Research Specifications
• 7.3. Standard mRNA Production
  • 7.3.1. Cataloged mRNA Variants
  • 7.3.2. Off-the-Shelf mRNA Selections

8. mRNA Synthesis & Manufacturing Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Advanced LNP Formulation Technology
• 8.3. Enzymatic Capping & Cap Analogues
• 8.4. Genetic Engineering & Codon Optimization
• 8.5. In Vitro Transcription
• 8.6. Plasmid DNA Template
• 8.7. Polyadenylation
• 8.8. RNA Purification Techniques

9. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale

• 9.1. Introduction
• 9.2. Commercial Scale
• 9.3. Lab Scale
• 9.4. Pilot Scale

10. mRNA Synthesis & Manufacturing Market, by Technology

• 10.1. Introduction
• 10.2. In Vitro Synthesis
• 10.3. In Vivo Synthesis

11. mRNA Synthesis & Manufacturing Market, by Application

• 11.1. Introduction
• 11.2. Therapeutics
  • 11.2.1. Cancer
  • 11.2.2. Infectious Diseases
  • 11.2.3. Rare Diseases
• 11.3. Vaccines
  • 11.3.1. Prophylactic Vaccines
  • 11.3.2. Therapeutic Vaccines

12. mRNA Synthesis & Manufacturing Market, by Usage

• 12.1. Introduction
• 12.2. Human Use
• 12.3. Veterinary Use

13. mRNA Synthesis & Manufacturing Market, by End-User

• 13.1. Introduction
• 13.2. Academic & Research Institutes
  • 13.2.1. Government Research Bodies
  • 13.2.2. University Laboratories
• 13.3. Contract Manufacturing Organizations
• 13.4. Pharmaceutical & Biotechnology Companies

14. Americas mRNA Synthesis & Manufacturing Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific mRNA Synthesis & Manufacturing Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa mRNA Synthesis & Manufacturing Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
  • 17.3.1. TriLink and Alphazyme's CleanScribe RNA Polymerase revolutionizes mRNA synthesis with reduced dsRNA formation
  • 17.3.2. Partnership between Telesis Bio and Beckman Coulter Life Sciences transforms DNA and mRNA synthesis through scalable and high-fidelity biofoundries
  • 17.3.3. Strategic partnership in mRNA synthesis, Primrose Bio, and ExPLoRNA transform therapeutic advancements through innovation
  • 17.3.4. Strategic acquisition of echelon biosciences by VION biosciences to increase mRNA therapies and life science offerings
  • 17.3.5. GSK collaborates with Touchlight to revolutionize mRNA vaccine production using advanced dbDNA technology
  • 17.3.6. Applied DNA secures patent for innovative Linea IVT technology advancing mRNA synthesis efficiency
  • 17.3.7. WACKER unveils mRNA competence center in Germany to expand global pandemic preparedness and biotech innovation
  • 17.3.8. Takara Bio launched genetically enhanced PrimeCap T7 RNA polymerase, revolutionizing safe mRNA synthesis for advanced therapeutics
  • 17.3.9. TriLink BioTechnologies Expands Late-Phase mRNA Drug Manufacturing with New San Diego Facility
  • 17.3.10. Strategic alliance between PackGene Biotech and Kudo Biotechnology transforms global mRNA manufacturing landscape with comprehensive end-to-end solutions
• 17.4. Strategy Analysis & Recommendation
  • 17.4.1. GenScript Biotech Corporation
  • 17.4.2. Thermo Fisher Scientific Inc.
  • 17.4.3. Samsung Biologics Co., Ltd.
  • 17.4.4. Danaher Corporation

Companies Mentioned

• 1. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
• 2. Bio-Synthesis Inc.
• 3. Creative Biogene
• 4. Creative Biolabs
• 5. Croyez Bioscience Co., Ltd.
• 6. Danaher Corporation
• 7. FUJIFILM Wako Pure Chemical Corporation
• 8. Genewiz by Azenta Life Sciences
• 9. GenScript Biotech Corporation
• 10. Jena Bioscience GmbH by Enzo Biochem Inc.
• 11. Lonza Group Ltd.
• 12. Merck KGaA
• 13. New England Biolabs, Inc.
• 14. PackGene Biotech, Inc.
• 15. Promega Corporation
• 16. Samsung Biologics Co., Ltd.
• 17. Sartorius AG
• 18. ST Pharm
• 19. System Biosciences, LLC
• 20. Takara Bio Inc.
• 21. Telesis Bio Inc.
• 22. Thermo Fisher Scientific Inc.
• 23. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
• 24. WuXi Biologics (Cayman) Inc